Timing of dual antiplatelet therapy in acute coronary syndrome: a problem of coronary artery bypass grafting accessibility for patients
Open Access
- 14 September 2020
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (8), 3812
- https://doi.org/10.15829/1560-4071-2020-3812
Abstract
The feasibility of dual antiplatelet therapy as early as possible in patients with ST-segment elevation acute coronary syndrome, where percutaneous coronary intervention is recommended, has been proven: it improves treatment outcomes by reducing the risk of adverse ischemic events, including stent thrombosis and myocardial infarction.This article provides a detailed analysis of the evidence data and current recommendations on the validity and timing of dual antiplatelet therapy for acute coronary syndrome. The emphasis is made on the controversy regarding the early dual antiplatelet therapy in non-ST-segment elevation acute coronary syndrome. The rationale for using dual antiplatelet therapy only after coronary angiography and determining the revascularization strategy is described, which should increase the accessibility of coronary artery bypass graft surgery for patients.Keywords
This publication has 26 references indexed in Scilit:
- 2014 ESC/EACTS Guidelines on myocardial revascularizationEuropean Heart Journal, 2014
- Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2014
- Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trialEuropean Heart Journal, 2014
- Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 TrialJournal of Cardiovascular Translational Research, 2013
- Efficacy of Clopidogrel Reloading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention During Chronic Clopidogrel Therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] Trial)The American Journal of Cardiology, 2013
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic EventsThe New England Journal of Medicine, 2013
- Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial InfarctionThe New England Journal of Medicine, 2011
- Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trialClinical Research in Cardiology, 2011
- Benefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registriesClinical Therapeutics, 2008
- Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of ClopidogrelCirculation, 2005